TrialPharmacogenetics and genomics2009

Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.

Amy I Lynch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.